Asset Details
Do you wish to reserve the book?
Adalimumab in Patients with Active Noninfectious Uveitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adalimumab in Patients with Active Noninfectious Uveitis
Do you wish to request the book?
Adalimumab in Patients with Active Noninfectious Uveitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adalimumab in Patients with Active Noninfectious Uveitis
2016
Overview
This phase 3 trial showed that persons with noninfectious uveitis who received adalimumab were more likely to have serious adverse events and less likely to have ophthalmic inflammation, uveitic flare, or visual impairment than were those who received placebo.
Noninfectious uveitis is a group of vision-threatening diseases that are characterized by intraocular inflammation; it can occur as a syndrome isolated to the eye or in association with a systemic condition. Uveitis has an estimated incidence of 17 to 52 cases per 100,000 person-years
1
and is estimated to cause 10 to 15% of cases of blindness in Western countries.
2
,
3
Glucocorticoids remain the mainstay of therapy despite their well-known ocular and systemic adverse effects.
4
–
6
Thus, there is a large unmet medical need for and a great interest in identifying more effective, glucocorticoid-sparing therapies, ideally targeting specific mediators of the . . .
Publisher
Massachusetts Medical Society
Subject
